Key Developments: Warner Chilcott Plc (WCRX.O)
20.61USD
21 May 2013
$1.01 (+5.15%)
$19.21
$19.63
$20.64
$19.63
24,530,934
6,211,633
$20.64
$10.85
Latest Key Developments (Source: Significant Developments)
Actavis Inc To Acquire Warner Chilcott Plc
Actavis Inc and Warner Chilcott plc announced they have entered into a definitive agreement under which Actavis will acquire Warner Chilcott plc in a stock-for-stock transaction valued at approximately $8.5 billion. The proposed transaction has been unanimously approved by the Boards of Directors of Actavis, Inc. and Warner Chilcott plc, and is supported by the management teams of both companies. At the close of the transaction (the Effective Date), which is expected by year-end 2013, Actavis and Warner Chilcott will be combined under a new company incorporated in Ireland, where Warner Chilcott is currently incorporated. The newly created company, which is expected to be called Actavis plc, or a variant thereof (New Actavis), will be led by the current Actavis leadership team. Under the terms of the Transaction Agreement, at closing Warner Chilcott shareholders will receive 0.160 shares of New Actavis for each Warner Chilcott share they own, which equates to a value of $20.08 per Warner Chilcott share based on Actavis' closing share price of $125.50 on May 17, 2013. Actavis shareholders will receive one share of New Actavis for each Actavis share they own upon closing. Immediately after the close of the transaction, Warner Chilcott shareholders are expected to own approximately 23% of New Actavis. Shares of New Actavis are expected to trade on the New York Stock Exchange under the ticker symbol ACT. Full Article
Actavis Inc In Early Talks To Buy Warner Chilcott Plc-DJ
Dow Jones reported that Actavis Inc In is in early-stage talks to buy Warner Chilcott PLC. Full Article
Warner Chilcott PLC Declares Semi Annual Cash Dividend
Warner Chilcott PLC announced that on May 7, 2013, it declared a semi-annual cash dividend under dividend policy (the Dividend Policy) in the amount of $0.25 per share, payable June 14, 2013 to shareholders of record on May 31, 2013. Full Article
Warner Chilcott PLC Announces FDA Approval Of New Oral Contraceptive
Warner Chilcott PLC announced that the United States Food and Drug Administration (FDA) has approved a new oral contraceptive, norethindrone acetate and ethinyl estradiol chewable tablets and ferrous fumarate tablets, for the prevention of pregnancy. This product does not currently have a brand name. The Company anticipates that it will commercially launch the product in early August 2013. Full Article
Warner Chilcott PLC Announces Semi-Annual Cash Dividend Of $0.25 Per Share
Warner Chilcott PLC announced that Board of Directors declared a semi-annual cash dividend in the amount of $0.25 per share, payable June 14, 2013, to shareholders of record at the close of business on May 31, 2013. Full Article
Warner Chilcott PLC Announces Management Changes
Warner Chilcott PLC announced that Board of Directors has voted unanimously to appoint Paul Herendeen, the Company's Executive Vice President and Chief Financial Officer, to the Company's Board effective as of May 2, 2013. Mr. Herendeen will continue to serve as Executive Vice President and Chief Financial Officer of the Company. Full Article
Warner Chilcott PLC Announces FDA Approval of New Oral Contraceptive
Warner Chilcott PLC announced that the United States Food and Drug Administration (FDA) has approved MINASTRINTM 24 FE (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) for the prevention of pregnancy. MINASTRIN 24 FE is manufactured for Warner Chilcott by a third party. The Company does not expect to be in a position to commercially launch MINASTRIN 24 FE during 2013. Full Article
Warner Chilcott PLC Comments On Q1, Q2, Q3 And Q4 2013 Revenue Guidance-Conference Call
Warner Chilcott PLC announced that, it expects first quarter of 2013 revenues would start higher, and trend lower into second quarter, third quarter and fourth quarter of 2013. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $589 million for first quarter of 2013, revenue of $584 million for second quarter of 2013, revenue of $587 million for third quarter of 2013 and revenue of $581 million for fourth quarter of 2013. Full Article
Warner Chilcott PLC Issues FY 2013 Revenue Guidance In Line With Analysts' Estimates
Warner Chilcott PLC announced that for fiscal 2013, it expects total revenue to be in the range of $2.3-$2.4 billion. The 2013 revenue expectations reflect, among other things, the anticipated growth of certain of the Company's promoted products, including LO LOESTRIN FE and ESTRACE CREAM, which the Company believes will be more than offset by the anticipated continued decline in ACTONEL revenues. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $2.4 billion for fiscal 2013. Full Article
Warner Chilcott PLC Reaffirms FY 2012 Revenue Guidance-Conference Call
Warner Chilcott PLC reaffirmed fiscal 2012 revenue guidance to be in the range of $2.4-$2.5 billion. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $2.5 billion for fiscal 2012. Full Article
PRESS DIGEST - Financial Times - May 21
Essar Oil to sign fuel-for-cash deal with China Development Bank
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
